117 related articles for article (PubMed ID: 8627531)
1. Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase.
McAdam B; Keimowitz RM; Maher M; Fitzgerald DJ
J Pharmacol Exp Ther; 1996 May; 277(2):559-64. PubMed ID: 8627531
[TBL] [Abstract][Full Text] [Related]
2. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
[TBL] [Abstract][Full Text] [Related]
4. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
5. Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.
Keimowitz RM; Pulvermacher G; Mayo G; Fitzgerald DJ
Circulation; 1993 Aug; 88(2):556-61. PubMed ID: 8339418
[TBL] [Abstract][Full Text] [Related]
6. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production.
Riondino S; Trifirò E; Principessa L; Mascioletti S; Di Renzo L; Gaudio C; Biasucci LM; Crea F; Pulcinelli FM
Thromb Res; 2008; 122(3):359-65. PubMed ID: 18295304
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
9. Umbilical cord serum levels of thromboxane B2 in term infants of women who participated in a placebo-controlled trial of low-dose aspirin.
Parker CR; Hauth JC; Goldenberg RL; Cooper RL; Dubard MB
J Matern Fetal Med; 2000; 9(4):209-15. PubMed ID: 11048830
[TBL] [Abstract][Full Text] [Related]
10. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
[TBL] [Abstract][Full Text] [Related]
11. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
[TBL] [Abstract][Full Text] [Related]
12. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function.
Cerletti C; Bonati M; del Maschio A; Galletti F; Dejana E; Tognoni G; de Gaetano G
J Lab Clin Med; 1984 Jun; 103(6):869-77. PubMed ID: 6726057
[TBL] [Abstract][Full Text] [Related]
14. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma".
Cerletti C; Latini R; Del Maschio A; Galletti F; Dejana E; de Gaetano G
Thromb Haemost; 1985 Jun; 53(3):415-8. PubMed ID: 4049312
[TBL] [Abstract][Full Text] [Related]
15. A prostacyclin-sparing effect of indobufen vs. aspirin.
De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
[TBL] [Abstract][Full Text] [Related]
17. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.
Evangelista V; Manarini S; Di Santo A; Capone ML; Ricciotti E; Di Francesco L; Tacconelli S; Sacchetti A; D'Angelo S; Scilimati A; Sciulli MG; Patrignani P
Circ Res; 2006 Mar; 98(5):593-5. PubMed ID: 16484611
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
19. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
20. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid.
Clappers N; van Oijen MG; Sundaresan S; Brouwer MA; Te Morsche RH; Keuper W; Peters WH; Drenth JP; Verheugt FW
Thromb Haemost; 2008 Jul; 100(1):70-5. PubMed ID: 18612540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
